[HTML][HTML] Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
S Kanokudom, J Chansaenroj, N Suntronwong… - International Journal of …, 2023 - Elsevier
Objectives To report the safety and immunogenicity profile of a protein subunit vaccine
(Covovax TM) given as a third (booster) dose to individuals primed with different primary …
(Covovax TM) given as a third (booster) dose to individuals primed with different primary …
The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA. 4/BA. 5
S Kanokudom, J Chansaenroj, N Suntronwong… - Vaccines, 2023 - mdpi.com
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth
dose using monovalent mRNA vaccines after different three-dose regimens and to compare …
dose using monovalent mRNA vaccines after different three-dose regimens and to compare …
Pneumonic Plague Protection Induced by a Monophosphoryl Lipid A Decorated Yersinia Outer‐Membrane‐Vesicle Vaccine
S Majumder, S Das, P Li, N Yang, H Dellario, H Sui… - Small, 2024 - Wiley Online Library
A new Yersinia pseudotuberculosis mutant strain, YptbS46, carrying the lpxE insertion and
pmrF‐J deletion is constructed and shown to exclusively produce monophosphoryl lipid A …
pmrF‐J deletion is constructed and shown to exclusively produce monophosphoryl lipid A …
Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review
Background The baculovirus expression vector system has been developed for expressing
a wide range of proteins, including enzymes, glycoproteins, recombinant viruses, and …
a wide range of proteins, including enzymes, glycoproteins, recombinant viruses, and …
Immunogenicity and durability against Omicron BA. 1, BA. 2 and BA. 4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with …
S Assawakosri, S Kanokudom, N Suntronwong… - Heliyon, 2024 - cell.com
Background Several countries have authorized a booster vaccine campaign to combat the
spread of COVID-19. Data on persistence of booster vaccine‐induced immunity against new …
spread of COVID-19. Data on persistence of booster vaccine‐induced immunity against new …
Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine
R Chaiwarith, P Winichakoon, P Salee, T Sudjaritruk… - Scientific Reports, 2023 - nature.com
This study followed healthcare personnel (HCP) who had completed a primary series of
CoronaVac and then received the third and fourth doses of COVID-19 vaccine. The primary …
CoronaVac and then received the third and fourth doses of COVID-19 vaccine. The primary …
Immunogenicity, safety, and reactogenicity of a half-versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or …
T Batmunkh, KA Moore, H Thomson… - The Lancet Regional …, 2024 - thelancet.com
Background COVID-19 vaccine booster doses restore vaccine effectiveness lost from
waning immunity and emerging variants. Fractional dosing may improve COVID-19 booster …
waning immunity and emerging variants. Fractional dosing may improve COVID-19 booster …
The humoral response to COVID-19 vaccinations can predict the booster effect on health care workers—toward personalized vaccinations?
O Freund, A Harish, A Breslavsky, O Wand… - Journal of Public …, 2024 - academic.oup.com
Background Waning immunity after the coronavirus disease 2019 (COVID-19) vaccinations
creates the constant need of boosters. Predicting individual responses to booster vaccines …
creates the constant need of boosters. Predicting individual responses to booster vaccines …
A randomized clinical trial of a fractional low dose of BNT162b2 booster in adults following AZD1222
R Nantanee, W Jantarabenjakul, P Jaru-Ampornpan… - Vaccines, 2022 - mdpi.com
In the era of globally predominant omicron strains, a COVID-19 booster vaccine is needed.
Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after …
Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after …
COVID-19 booster vaccination: increasing immunity against life-threatening infection
R Yorsaeng, K Atsawawaranunt, A Riad - Frontiers in Public Health, 2024 - frontiersin.org
The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has
caused the global transmission of Coronavirus disease 2019 (COVID-19) and continues to …
caused the global transmission of Coronavirus disease 2019 (COVID-19) and continues to …